Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Cited by (629)

Items 101–200 of 629

1. SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence
   Elizabeth‐Barbara Tatsi, Filippos Filippatos, Athanasios G. Michos · 2021 · Epidemiology and Infection
2. An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
   Fatemeh Bayani, Negin Safaei Hashkavaei, Sareh Arjmand, Shokouh Rezaei, Vuk Uskoković, Mahdi Alijanianzadeh, Vladimir Nikolaevich Uversky, Seyed Omid Ranaei Siadat, Sina Mozaffari‐Jovin, Yahya Sefidbakht · 2023 · Progress in Biophysics and Molecular Biology
3. The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
   Chang Liu, Da-Ming Zhou, Rungtiwa Nutalai, H. Duyvesteyn, Aekkachai Tuekprakhon, H. Ginn, W. Dejnirattisai, P. Supasa, A. Mentzer, Bei-Bei Wang et al. · 2021 · Cell Host and Microbe
4. Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city
   Cecília Ártico Banho, Lívia Sacchetto, Guilherme Rodrigues Fernandes Campos, Cíntia Bittar, Fábio Sossai Possebon, Leila Sabrina Ullmann, Beatriz de Carvalho Marques, Gislaine Celestino Dutra da Silva, Marília Mazzi Moraes, Maisa Carla Pereira Parra et al. · 2022 · Communications Medicine
5. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
   Shabir Ahmed Madhi, Dhayendre Moodley, Sherika Hanley, Moherndran Archary, Zaheer Hoosain, Umesh Lalloo, Cheryl Emily Louw, Lee Fairlie, Leon Frederik Fouche, Mduduzi Sandile Lawrance Masilela et al. · 2022 · The Lancet HIV
6. Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines
   Rupsha Fraser, Aurelio Orta Resendiz, Alexander Mazein, David Harold Dockrell · 2023 · Trends in Molecular Medicine
7. HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave
   Farina Karim, Inbal Gazy, Sandile Cele, Yenzekile Zungu, Robert Krause, Mallory P. Bernstein, Khadija Khan, Yashica Ganga, Hylton E. Rodel, Ntombifuthi Mthabela et al. · 2021 · eLife
8. Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa
   Krishna P. Reddy, Kieran P. Fitzmaurice, Justine A. Scott, Guy Harling, Richard John Lessells, Christopher Panella, Fatma M. Shebl, Kenneth A. Freedberg, Mark Jacob Siedner · 2021 · Nature Communications
9. SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021
   Mohammad Alkhatib, Valentina Svicher, Romina Salpini, Francesca Alessandra Ambrosio, Maria Concetta Bellocchi, Luca Carioti, Lorenzo Piermatteo, Rossana Scutari, Giosuè Costa, Anna Artese et al. · 2021 · Microbiology Spectrum
10. COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy
    Alexander Domnich, Andrea Orsi, Carlo-Simone Trombetta, Giulia Guarona, Donatella Panatto, Giancarlo Icardi · 2022 · Pharmaceuticals
11. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
    María Eugenia Toledo-Romaní, Mayra García Carmenate, Carmen Valenzuela‐Silva, Waldemar Baldoquín Rodríguez, Marisel Martínez-Pérez, Meiby Rodríguez-González, Beatriz Paredes-Moreno, Ivis Mendoza-Hernández, Raúl González-Mugica, Oscar Samón-Tabío et al. · 2022 · The Lancet Regional Health - Americas
12. Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review
    Kadhim Hayawi, Sakib Shahriar, Mohamed Adel Serhani, Hany Alashwal, Mohammad Mehedy Masud · 2021 · Vaccines
13. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
    Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, Matthew Gagné, Lilin Lai, Juan I. Moliva, Barbara J. Flynn, Angela Choi, Matthew Koch, Kathryn E. Foulds et al. · 2021 · Nature Immunology
14. Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies
    Gautam Sanyal · 2022 · npj Vaccines
15. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
    Sue Ann Costa Clemens, Pedro M. Folegatti, Katherine R. W. Emary, Lily Yin Weckx, Jeremy Ratcliff, Sagida Bibi, Ana Verena Almeida Mendes, Eveline Pı́polo Milan, Ana Maria Pittella, Alexandre Vargas Schwarzbold et al. · 2021 · Nature Communications
16. NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses
    Carolyn Rydyznski Moderbacher, Christina Kim, José Mateus, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Daniela Weiskopf, Alessandro Sette, Louis F Fries, Gregory M. Glenn et al. · 2022 · Journal of Clinical Investigation
17. Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants
    Yinfeng Kang, Cong Sun, Jing Sun, Chu Xie, Zhen Zhuang, Hui-Qin Xu, Zheng Liu, Yihao Liu, Sui Peng, Runyu Yuan et al. · 2022 · Nature Communications
18. COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa
    Quarraisha Abdool Karim, Cheryl Baxter · 2022 · Current HIV/AIDS Reports
19. Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 –May 2021
    Lamprini Veneti, Elina Marjukka Seppälä, Margrethe Larsdatter Storm, Beatriz Valcárcel Salamanca, Eirik Alnes Buanes, Nina Aasand, Umaer Naseer, Karoline Bragstad, Olav Hungnes, Håkon Bøås et al. · 2021 · PLoS ONE
20. The way of SARS-CoV-2 vaccine development: success and challenges
    Yetian Dong, Tong Dai, Bin Wang, Lei Zhang, Linghui Zeng, Jun Huang, Haiyan Yan, Long Zhang, Fangfang Zhou · 2021 · Signal Transduction and Targeted Therapy
21. Covid-19: virology, variants, and vaccines
    Megan Young, Harry Crook, Janet T. Scott, Paul Edison · 2022 · BMJ Medicine
22. SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines
    Desh Deepak Singh, Amna Parveen, Dharmendra Kumar Yadav · 2021 · Frontiers in Cellular and Infection Microbiology
23. A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders
    Farnoosh Seirafianpour, Homa Pourriyahi, Milad Gholizadeh Mesgarha, Arash Pour Mohammad, Zoha Shaka, Azadeh Goodarzi · 2022 · Dermatologic Therapy
24. Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics
    Aleksandr V. Kudriavtsev, Anna Vakhrusheva, Valery Nikolaevich Novoseletsky, Marine E. Bozdaganyan, К. В. Шайтан, Mikhail P. Kirpichnikov, Olga S. Sokolova · 2022 · Viruses
25. COVID-19 vaccines in pregnancy
    Marta Coelho Nunes, Shabir Ahmed Madhi · 2022 · Trends in Molecular Medicine
26. SARS-CoV-2: phenotype, genotype, and characterization of different variants
    Mohammadreza Saberiyan, Elham Karimi, Zahra Khademi, Parvaneh Movahhed, Amir Safi, Ameneh Mehri Ghahfarrokhi · 2022 · Cellular & Molecular Biology Letters
27. Development of a model-inference system for estimating epidemiological characteristics of SARS-CoV-2 variants of concern
    Wan Yang, Jeffrey L. Shaman · 2021 · Nature Communications
28. On the role of data, statistics and decisions in a pandemic
    Beate Jahn, Sarah Friedrich, Joachim Behnke, Joachim Engel, Ursula Garczarek, Ralf Thomas Münnich, Markus Pauly, Adalbert Wilhelm, Olaf Wolkenhauer A, Markus Zwick et al. · 2022 · AStA Advances in Statistical Analysis
29. Putative Role of Vitamin D for COVID-19 Vaccination
    Sheng-Kang Chiu, Kuo‐Wang Tsai, Chia‐Chao Wu, Cai‐Mei Zheng, Chung‐Hsiang Yang, Wan‐Chung Hu, Yi‐Chou Hou, Kuo‐Cheng Lu, You‐Chen Chao · 2021 · International Journal of Molecular Sciences
30. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
    Jinal N. Bhiman, Simone I. Richardson, Bronwen E. Lambson, Prudence Kgagudi, Nonkululeko B. Mzindle, Haajira Kaldine, Carol E. Crowther, Glenda Gray, Linda‐Gail Bekker, Anthonet Lombard Koen et al. · 2023 · Scientific Reports
31. Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens
    Maddy L. Newby, Joel D. Allen, Max Crispin · 2023 · Biotechnology Advances
32. Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and Reports
    Julia Shapiro, Natalie E. Dean, Zachary J. Madewell, Yang Yang, M. Elizabeth Halloran, Ira M. Longini · 2021 · medRxiv
33. Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines
    Rekha R. Rapaka, Alan S. Cross, Monica A. McArthur · 2021 · Vaccines
34. Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021
    Kun Xu, Lianpan Dai, George F. Gao · 2021 · International Immunology
35. From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines
    Diana Ofelia Lopez-Cantu, Xichi Wang, Hector Carrasco-Magallanes, Samson Afewerki, Xingcai Zhang, Joseph Vincent Bonventre, Guillermo U. Ruiz‐Esparza · 2022 · Nano-Micro Letters
36. Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines
    Mohammad Reza Zinatizadeh, Peyman Kheirandish Zarandi, Maryam Zinatizadeh, Mohammad Hadi Yousefi, Jaffar Amani, Nima Rezaei · 2021 · Biomedicine & Pharmacotherapy
37. Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
    Vincent Pavot, Catherine Berry, Michael Kishko, Natalie G. Anosova, Dean Huang, Tim Tibbitts, Alice Raillard, Sylviane Gautheron, Cindy Gutzeit, Marguerite Koutsoukos et al. · 2022 · Nature Communications
38. Intranasal COVID-19 vaccine induces respiratory memory T cells and protects K18-hACE mice against SARS-CoV-2 infection
    Béré Diallo, Caitlín Ní Chasaide, Ting Y. Wong, Pauline Schmitt, Katherine S. Lee, Kelly L. Weaver, Olivia A. Miller, Melissa Cooper, Seyed Davoud Jazayeri, Fredrick Heath Damron et al. · 2023 · npj Vaccines
39. Virus‐like particles as powerful vaccination strategy against human viruses
    Ikbel Hadj Hassine, Manel Ben M’hadheb-Gharbi, Mohammed A. Almalki, Jawhar Gharbi · 2023 · Reviews in Medical Virology
40. SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations
    Wan-Ting Yang, Wei-Hsuan Huang, Tsai-Ling Liao, Tzu-Hung Hsiao, Han-Ni Chuang, Po-Yu Liu · 2022 · Infection and Drug Resistance
41. Willingness to Receive COVID-19 Vaccination Among People Living With HIV and AIDS in China: Nationwide Cross-sectional Online Survey
    Xiaojie Huang, Maohe Yu, Gengfeng Fu, Guanghua Lan, Linghua Li, Jianzhou Yang, Ying Qiao, Jin Zhao, Han‐Zhu Qian, Xiangjun Zhang et al. · 2021 · JMIR Public Health and Surveillance
42. Protein subunit vaccines: Promising frontiers against COVID-19
    Vivek P. Chavda, Eswara Naga Hanuma Kumar Ghali, Pankti C. Balar, Subhash C. Chauhan, Nikita Tiwari, Somanshi Shukla, Mansi Athalye, Vandana Bharat Patravale, Vasso Apostolopoulos, Murali Mohan Yallapu · 2024 · Journal of Controlled Release
43. Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic
    Charles Yap, Abulhassan Ali, Amogh Prabhakar, Akul Prabhakar, Aman Pal, Ying Yi Lim, Pramath Kakodkar · 2021 · Therapeutic Advances in Vaccines and Immunotherapy
44. Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa
    Bavesh Davandra Kana, Patrick B. Arbuthnot, Benjamin K Botwe, Yahya Essop Choonara, Fatima Hassan, Hechmi Louzir, Precious Matsoso, Penny L. Moore, Apollo Muhairwe, Kubendran Naidoo et al. · 2023 · The Lancet Infectious Diseases
45. COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations
    Zhipeng Yan, Ming Yang, Ching‐Lung Lai · 2021 · Vaccines
46. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications
    Lijun Chen, Jingjing Qu, Farhin Shaheed Kalyani, Qi Zhang, Lingzhi Fan, Yangxin Fang, Yifei Li, Charlie Xiang · 2022 · Cellular and Molecular Life Sciences
47. Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice
    Adrian Rice, Mohit S. Verma, Annie Shin, Lise Zakin, Peter A. Sieling, Shiho Tanaka, Joseph P. Balint, Kyle Dinkins, Helty Adisetiyo, Brett Morimoto et al. · 2021 · Scientific Reports
48. Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients
    Xiuyuan Lu, Yuki Hosono, Masamichi Nagae, Shigenari Ishizuka, Eri Ishikawa, Daisuke Motooka, Yuki Ozaki, Nicolas Sax, Yuichi Maeda, Yasuhiro Kato et al. · 2021 · The Journal of Experimental Medicine
49. Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant
    Bassel Akache, Tyler Milston Renner, Anh Tran, Lise Deschatelets, Renu Dudani, Blair A. Harrison, Diana Duque, Julie Haukenfrers, Martín A. Rossotti, Francis Gaudreault et al. · 2021 · Scientific Reports
50. SARS-CoV-2 Vaccines: Where Are We Now?
    Katie L. Flanagan, Chandini Raina MacIntyre, Peter Bruce McIntyre, Michael R. Nelson · 2021 · The Journal of Allergy and Clinical Immunology In Practice
51. Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants
    Saskia Meyer, Isaac Blaas, Ravi Chand Bollineni, Marina Delić-Šarac, Trung The Tran, Cathrine F. Knetter, Ke‐Zheng Dai, Torfinn Støve Madssen, John Torgils Vaage, Alice Gustavsen et al. · 2023 · Cell Reports
52. Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use
    Sagheer Ahmed, Saeed Khan, Imran Imran, Fadwa Al Mughairbi, Fahad Sultan Sheikh, Javid Hussain, Ajmal Khan, Ahmed Al‐Harrasi · 2021 · Vaccines
53. Peculiarities of the T Cell Immune Response in COVID-19
    Dmitry Anatolievich Kudlay, И.А. Кофиади, Musa Rakhimovich Khaitov · 2022 · Vaccines
54. Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis
    Natalina Sutton, Alberto San Francisco Ramos, Emily R. Beales, David Smith, Sabina Ikram, Eva P. Galiza, Yingfen Hsia, Paul Trafford Heath · 2022 · Expert Review of Vaccines
55. SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice
    Katherine S. Lee, Ting Y. Wong, Brynnan P. Russ, Alexander M. Horspool, Olivia A. Miller, Nathaniel A. Rader, Jerome P. Givi, Michael T. Winters, Zeriel Y. Wong, Holly A. Cyphert et al. · 2022 · PLoS ONE
56. Clinical Severity of COVID-19 Patients Admitted to Hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave
    Waasila Jassat, Salim S. Abdool Karim, Caroline Mudara, Richard Welch, Lovelyn Ozougwu, Michelle J. Groome, Nevashan Govender, Anne von Gottberg, Nicole Wolter, DATCOV Author Group et al. · 2021 · SSRN Electronic Journal
57. Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers
    Billy J. Gardner, Auston Marm Kilpatrick · 2024 · Viruses
58. Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
    Lanying Du, Yang Yang, Xiujuan Zhang, Fang Li · 2021 · Nanoscale
59. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
    Pablo García-Valtanen, Christopher M. Hope, Makutiro Ghislain Masavuli, Arthur Eng Lip Yeow, Harikrishnan Balachandran, Zelalem Addis Mekonnen, Zahraa Al-Delfi, Arunasingam Abayasingam, David Agapiou, Alberto Ospina Stella et al. · 2022 · Cell Reports Medicine
60. Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis
    Fan Jiang, Yinping Liu, Yong Xue, Peng Cheng, Jie Wang, Jianqi Lian, Wenping Gong · 2023 · International Immunopharmacology
61. COVID-19: comprehensive review on mutations and current vaccines
    Ananda Vardhan Hebbani, Swetha Pulakuntla, Padmavathi Pannuru, Sreelatha Aramgam, Kameswara Rao Badri, Vaddi Damodara Reddy · 2021 · Archives of Microbiology
62. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
    Xiao‐Feng He, Jiao Su, Yu’nan Ma, Wenping Zhang, Shixing Tang · 2022 · Frontiers in Immunology
63. Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta)
    Jakob Trimpert, Julia Maria Adler, Kathrin Eschke, Azza Abdelgawad, Theresa C. Firsching, Nadine Ebert, Tran Thi Nhu Thao, Achim Dieter Gruber, Volker Thiel, Nikolaus Osterrieder et al. · 2021 · Science Advances
64. Principles of SARS-CoV-2 glycosylation
    Himanshi Chawla, Elisa Fadda, Max Crispin · 2022 · Current Opinion in Structural Biology
65. The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD
    Fatima Amanat, Mahima Thapa, Tinting Lei, Shaza M. Sayed Ahmed, Daniel C. Adelsberg, Juan Manuel Carreño, Shirin Strohmeier, Aaron J. Schmitz, Sarah Zafar, Julian Q. Zhou et al. · 2021 · medRxiv
66. mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants
    Yunkai Yu, Dominic Esposito, Zhigang Kang, Jianming Lü, Alan Thomas Remaley, Valeria De Giorgi, Leonard N. Chen, Kamille A. West, Liang Cao · 2022 · Scientific Reports
67. COVID-19 vaccines: Immune correlates and clinical outcomes
    Shant H. Mahrokhian, Lisa H. Tostanoski, Samuel J. Vidal, Dan H. Barouch · 2024 · Human Vaccines & Immunotherapeutics
68. Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa
    E. du Bruyn, C. Stek, Remi Daroowala, Q. Said-Hartley, M. Hsiao, Georgia Schafer, R. Goliath, F. Abrahams, A. Jackson, S. Wasserman et al. · 2023 · Nature Communications
69. The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome
    Roy Malcolm Anderson, Carolin Vegvari, T. Déirdre Hollingsworth, Li Pi, Rosie Maddren, Chi Wai Ng, Rebecca F. Baggaley · 2021 · Interface Focus
70. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness
    SubbaRao V. Tulimilli, Siva Dallavalasa, Chaithanya G. Basavaraju, Vinay Kumar Rao, Prashanth Chikkahonnaiah, SubbaRao V. Madhunapantula, Ravindra P. Veeranna · 2022 · Vaccines
71. Nanocarrier vaccine therapeutics for global infectious and chronic diseases
    Faizan Zarreen Simnani, Dibyangshee Singh, Paritosh Patel, Anmol Choudhury, Adrija Sinha, Aditya Nandi, Shailesh Kumar Samal, Suresh K. Verma, Pritam Kumar Panda · 2023 · Materials Today
72. SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
    Daniele Focosi, Marco Tuccori, Andreina Baj, Fabrizio Maggi · 2021 · Viruses
73. Impact of computational approaches in the fight against COVID-19: an AI guided review of 17 000 studies
    Francesco Napolitano, Xiaopeng Xu, Xin Gao · 2021 · Briefings in Bioinformatics
74. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV)
    Khadija Khan, Gila Lustig, Mallory P. Bernstein, Derseree Archary, Sandile Cele, Farina Karim, Muneerah Smith, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy et al. · 2021 · Clinical Infectious Diseases
75. Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19
    Wei Zhao, Weixin Chen, Juan Li, Meng Chen, Qin Li, Min Lv, Shanshan Zhou, Shuang Bai, Yali Wang, Lichi Zhang et al. · 2022 · mBio
76. Efficacy and safety of COVID‐19 vaccines: A network meta‐analysis
    Ahmad A. Toubasi, Thuraya Al-Sayegh, Yazan Y. Obaid, Sarah M. Al‐Harasis, Saif Aldeen AlRyalat · 2022 · Journal of Evidence-Based Medicine
77. SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies
    Petra Mlčochová, Steven A. Kemp, Mahesh Shanker Dhar, Guido Papa, Bo Meng, Swapnil Mishra, Charles Whittaker, Thomas A. Mellan, Isabella Ferreira, Rawlings P. Datir et al. · 2021 · Greater South Information System
78. The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape
    Darren P Martin, Steven Weaver, Houryiah Tegally, Emmanuel James San, Stephen D. Shank, Eduan Wilkinson, Alexander G. Lucaci, Jennifer Giandhari, Sureshnee Naidoo, Yeshnee Pillay et al. · 2021 · PubMed
79. Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors
    Rita E. Chen, Matthew J. Gorman, Daniel Y. Zhu, Juan Manuel Carreño, Dansu Yuan, Laura A. VanBlargan, Samantha Burdess, Douglas A. Lauffenburger, Wooseob Kim, Jackson S. Turner et al. · 2021 · Med
80. Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology
    Jamie M. Caldwell, Xuan Le, Lorin McIntosh, Michael T. Meehan, Samson T. Ogunlade, Romain R. Ragonnet, Genevieve K. O’Neill, James McCracken Trauer, Emma Sue McBryde · 2021 · Paediatric Respiratory Reviews
81. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
    Rolando Pajón, Yamuna Devi Paila, Bethany Girard, Groves Dixon, Katherine A. Kacena, Lindsey Robert Baden, Hana M. El Sahly, Brandon J. Essink, Kathleen M. Mullane, Ian Frank et al. · 2022 · Nature Medicine
82. Immunoinformatics approach for multi-epitope vaccine design against structural proteins and ORF1a polyprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
    Khalid Mohamed Adam · 2021 · Tropical Diseases Travel Medicine and Vaccines
83. COVID-19: vaccines, efficacy and effects on variants
    Igor Rudan, Davies Adeloye, Aziz Sheikh · 2022 · Current Opinion in Pulmonary Medicine
84. The Immune Response to SARS-CoV-2 and Variants of Concern
    Elham Torbati, Kurt L. Krause, James E. Ussher · 2021 · Viruses
85. The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
    Yao Jiang, Qian Yun Wu, Peipei Song, Chongge You · 2022 · Frontiers in Medicine
86. Recent developments in SARS‐CoV‐2 vaccines: A systematic review of the current studies
    Mona Sadeghalvad, Amir Hossein Mansourabadi, Maryam Noori, Seyed Aria Nejadghaderi, Masoomeh Masoomikarimi, Masoumeh Alimohammadi, Nima Rezaei · 2022 · Reviews in Medical Virology
87. Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety
    Hanyan Meng, Jianhua Mao, Qing Ye · 2022 · Journal of Medical Virology
88. Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis
    Kai Wang, Lin Wang, Mingzhe Li, Bing Xie, Lu He, Meiyu Wang, Rumin Zhang, Nianzong Hou, Yi Zhang, Fusen Jia · 2022 · Frontiers in Medicine
89. Immune Imprinting and Implications for COVID-19
    Zhiqian Zhou, Julia Barrett, Xuan He · 2023 · Vaccines
90. Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro
    Binli Mao, Vu Thuy Khanh Le‐Trilling, Kai Wang, Denise Mennerich, Jie Hu, Zhenyu Zhao, Jiaxin Zheng, Yingying Deng, Benjamin Katschinski, Shilei Xu et al. · 2022 · Emerging Microbes & Infections
91. Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform
    Christopher Chevillard, Axelle Amen, Solène Besson, Dalil Hannani, Isabelle Bally, Valentin Dettling, Evelyne Gout, Christophe Moreau, Marlyse Buisson, Salomé Gallet et al. · 2022 · Molecular Therapy
92. SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
    Neil C. Dalvie, Lisa H. Tostanoski, Sergio A. Rodriguez‐Aponte, Kawaljit Kaur, Sakshi Bajoria, Ozan S. Kumru, Amanda Jezek Martinot, Abishek Chandrashekar, Katherine McMahan, Noe B. Mercado et al. · 2022 · Science Advances
93. Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021
    Kun Xu, Chunxiang Fan, Yuxuan Han, Lianpan Dai, George F. Gao · 2022 · International Immunology
94. Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
    Eddie Underwood, Lisa M. Dunkle, Shabir Ahmed Madhi, Cynthia L. Gay, Paul Trafford Heath, Karen L. Kotloff, Katherine Smith, Gordon Chau, Shirley Galbiati, Alice McGarry et al. · 2023 · Expert Review of Vaccines
95. Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease
    Ruth Elizabeth Drury, Susana Camara, Irina Chelysheva, Sagida Bibi, Katherine A. Sanders, Sally Felle, Katherine R. W. Emary, Daniel J. Phillips, Merryn Voysey, Daniela Mulari Ferreira et al. · 2024 · Nature Communications
96. A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2
    Yaochang Yuan, Xiantao Zhang, Ran Chen, Yuzhuang Li, Bolin Wu, Rong Li, Fan Zou, Xiancai Ma, Xuemei Wang, Qier Chen et al. · 2021 · Cell Reports
97. Development of Receptor Binding Domain (RBD)‐Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS‐CoV‐2 Delta and Other Variants
    Ran Chen, Xiantao Zhang, Yaochang Yuan, Xiaohui Deng, Bolin Wu, Zhihui Xi, Guanwen Wang, Yingtong Lin, Rong Li, Xuemei Wang et al. · 2022 · Advanced Science
98. Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition
    Thandeka Nkosi, Caroline Chasara, Anele Mbatha, Mza Nsimbi, Andrea Olga Papadopoulos, Tiza L Nguni, Farina Karim, Mohomed Yunus S Moosa, Inbal Gazy, Kondwani Jambo et al. · 2022 · eLife
99. Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France
    Benjamin Lefèvre, Laura Tondeur, Yoann Madec, Rebecca Grant, Bruno Lina, Sylvie van der Werf, Christian Rabaud, Arnaud L Fontanet, Antoine Legoff · 2021 · The Lancet Healthy Longevity
100. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus
     Yang Yu, Na Xu, Qi Cheng, Fēi Dèng, Meiqin Liu, Airu Zhu, Yuan‐Qin Min, Dan Zhu, Wenbo Huang, Xu Feng et al. · 2021 · Cell Reports